Section 4: Choosing a PI

Boosted PIs in ARV-naïve patients: Virological suppression at 48 weeks

Case Mathias graph5

Adapted from: 1. Eron J, et al. Lancet 2006;368:476–482;
2. Walmsley S, et al JAIDS 2009 Feb 12. [Epub ahead of print],
3. Molina J-M, et al. Lancet 2008;372:646–655
4. Gathe J, et al. JAIDS 2009 Feb 16. [Epub ahead of print]; .


CASTLE primary efficacy endpoint at Week 48: HIV RNA <50 c/mL (ITT-CVR NC=F)

Case Mathias graph6

Supporting analyses:
ITT-TLOVR: HIV RNA <50 c/mL: ATV/r 78%, LPV/r 76%; 1.9 (-3.6, 7.4) OT-VROC: HIV RNA <50 c/mL: ATV/r 84%, LPV/r 87%; -3.5 (-8.7, 1.8)

Case Mathias graph7

Adapted from Molina J-M, et al. Lancet 2008;372:646–655


CASTLE primary efficacy endpoint at Week 96: HIV RNA <50 c/mL (ITT-CVR NC=F)

Case Mathias graph8

Supporting analyses:
ITT-TLOVR: HIV RNA <50 c/mL: ATV/r 70%, LPV/r 63%; 6.6 (0.4, 12.7) OT-VROC: HIV RNA <50 c/mL: ATV/r 89%, LPV/r 88%; 1.6 (-3.1, 6.2)

Molina J-M, et al. ICAAC/IDSA, Washington, USA, 2008, Poster H-1250d


CASTLE ITT-confirmed virological response (NC=F) by qualifying HIV viral load

Case Mathias graph9

Adapted from Molina J-M, et al. Lancet 2008;372:646–655 2 Molina J-M, et al. ICAAC/IDSA, Washington, USA, 2008, Poster H-1250d


PI/r in treatment experienced patients: DRV/r or TPV/r vs. cPI(s): Viral load <50 copies/mL by ENF use at 48 weeks

Case Mathias graph10

Adapted from Hill A and Moyle. 46th ICAAC, San Francisco, CA, Sept. 27-30, 2006; Abst. H-1386.